Blood Vessels, Thrombosis & Hemostasis最新文献_第2页

Chronic endothelial inflammation in PWH leads to reduced circulating megakaryocyte progenitor cells

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2025-02-01 DOI: 10.1016/j.bvth.2024.100039

Tong Li , Colleen Hadigan , Jaeil Ahn , Chinmayee Mehta , Makheni Jean Pierre , Danial Mahmood , Metin Ozdemirli , Cooper James , Princy Kumar , Marta Catalfamo

引用次数: 0

Screening for gene variants causing inherited platelet disorders: are the cons always cons?

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2025-02-01 DOI: 10.1016/j.bvth.2024.100043

Loredana Bury , Emanuela Falcinelli , Anna Maria Mezzasoma , Giulia Ciarrocca Taranta , Elisa Giglio , Caterina Matteucci , Roberta La Starza , Alessandra Carotti , Paolo Gresele

引用次数: 0

In vivo neuroprotection in ischemic stroke by activated protein C requires β-arrestin 2

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2025-02-01 DOI: 10.1016/j.bvth.2024.100037

Biao Xiang ∗ , Yaoming Wang ∗ , Ruslan Rust , Kassandra Kisler , William J. Mack , José A. Fernández , Berislav V. Zlokovic † , John H. Griffin †

{"title":"In vivo neuroprotection in ischemic stroke by activated protein C requires β-arrestin 2","authors":"Biao Xiang ∗ , Yaoming Wang ∗ , Ruslan Rust , Kassandra Kisler , William J. Mack , José A. Fernández , Berislav V. Zlokovic † , John H. Griffin †","doi":"10.1016/j.bvth.2024.100037","DOIUrl":"10.1016/j.bvth.2024.100037","url":null,"abstract":"<div><h3>Abstract</h3><div>The protease activated protein C (APC) and its variants provide neuroprotection for murine ischemic stroke and mortality reduction for murine sepsis. For these actions, APC’s in vivo mechanism of action, similar to in vitro studies using cultured cells, involves protease activated receptor 1 (PAR1)–mediated biased signaling. APC/PAR1 signaling in vitro requires β-arrestin 2, an intracellular scaffold protein, and β-arrestin 2–initiated signaling can alter diverse intracellular signaling pathways. This study used a proximal transient middle cerebral artery occlusion model to study the neuroprotective actions of the signaling-selective APC variant, 3K3A-APC, in β-arrestin 2–deficient (<em>Arrb2</em><sup>–/–</sup>) mice. Based on quantitation of brain injuries, 3K3A-APC significantly limited brain injury in control mice to relatively small, localized areas, whereas 3K3A-APC’s protection was lost in <em>Arrb2</em><sup>–/–</sup> mice. Thus, the major in vitro mechanism of action that requires β-arrestin 2 for APC/PAR1 biased signaling is central to the in vivo mechanism of action for APC’s neuroprotection.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 1","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143093755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lossos C, Brown J, Sheikhbahaei S, et al. Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy. Blood Vessels Thromb Hemost. 2024;1(2):100006. Lossos C, Brown J, Sheikhbahaei S, et al. 特发性多中心 Castleman 病 - TAFRO 导致高水平的 mTOR 激活剂 SVEP1、组织因子和内皮细胞病变。血管血栓止血。2024;1(2):100006.

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-11-14 DOI: 10.1016/j.bvth.2024.100033

引用次数: 0

Artificial intelligence meets venous thromboembolism: informaticians’ insights on diagnosis, prevention, and management 人工智能与静脉血栓栓塞症：信息学家对诊断、预防和管理的见解

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-10-08 DOI: 10.1016/j.bvth.2024.100031

Anuranita Gupta , Barbara D. Lam , Sabrina Zerbey , Rachel P. Rosovsky , Leslie Lake , Laura Dodge , Alys Adamski , Nimia Reyes , Karon Abe , Ioannis Vlachos , Jeffrey I. Zwicker , Mara A. Schonberg , Rushad Patell

引用次数: 0

Is interrupting anticoagulation for thrombosis risk stratification safe? 为进行血栓风险分层而中断抗凝治疗安全吗？

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-09-23 DOI: 10.1016/j.bvth.2024.100028

Abhinav Mathur , Alexis Cairns , Henry G. Watson , Mohammed M. Khan

引用次数: 0

Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan 日本批准埃米珠单抗前后获得性 A 型血友病的临床特征和治疗结果

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-09-16 DOI: 10.1016/j.bvth.2024.100027

Daichi Kishi , Masashi Nishikubo , Yoshimitsu Shimomura , Takayuki Ishikawa , Tadakazu Kondo

{"title":"Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan","authors":"Daichi Kishi , Masashi Nishikubo , Yoshimitsu Shimomura , Takayuki Ishikawa , Tadakazu Kondo","doi":"10.1016/j.bvth.2024.100027","DOIUrl":"10.1016/j.bvth.2024.100027","url":null,"abstract":"<div><h3>Abstract</h3><div>Acquired hemophilia A (AHA) is a rare and potentially fatal bleeding disorder. Although bypassing agents effectively control active bleeding, their disadvantages, such as high cost and frequent administration, necessitate an agent that prevents recurrent bleeding events requiring bypassing agents. Emicizumab, a recombinant, humanized, bispecific monoclonal antibody with coagulation factor VIII (FVIII)–mimetic activity, was approved in Japan in 2022 for preventing bleeding in patients with AHA. However, owing to the rarity of the disease, real-world data on emicizumab use in AHA are scarce. Therefore, we aimed to assess the clinical characteristics and outcomes of 19 patients who were newly diagnosed with AHA before (non-emicizumab group [non-emi group], n = 12) and after (emicizumab group [emi group], n = 7) emicizumab approval in Japan. The median age, FVIII coagulation activity, and FVIII inhibitor titer were 81 vs 76 years, 1.0% vs 1.0%, and 43.75 vs 622 Bethesda units per mL in the non-emi and emi groups, respectively. Severe bleeding occurred in 14% of patients in the emi group, compared with 58% of patients in the non-emi group. Additionally, the doses of bypassing agents per patient were 43.4 vs 7, and the units of red blood cell transfusion per patient were 26.7 vs 4 in the non-emi and emi groups, respectively. Their hospital stays were median 73.5 days and 44 days, respectively. All patients treated with emicizumab maintained their activities of daily living (ADLs) and experienced no side effects. This study suggests that emicizumab effectively prevents bleeding in patients with AHA. Moreover, emicizumab may lead to shorter hospital stays, maintained ADLs, reduced costs, and improved prognosis in patients with AHA.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"1 4","pages":"Article 100027"},"PeriodicalIF":0.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative outcomes in patients with myeloproliferative neoplasms: a multicentric analysis of 354 surgical procedures 骨髓增生性肿瘤患者的围手术期疗效：对 354 例手术的多中心分析

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-09-16 DOI: 10.1016/j.bvth.2024.100026

Natasha Szuber , Harold J. Olney , Steve Dagenais Bellefeuille , Mégane Tanguay , Awatef Shehabeldeen , Saima Ahmed , Michaël Harnois , Jaroslav Prchal , Lambert Busque , Shireen Sirhan

引用次数: 0

Trauma-induced dysfibrinogenemia: the von Clauss assay does not accurately measure fibrinogen levels after injury 创伤诱发的纤维蛋白原不良血症：冯克劳斯测定法不能准确测量受伤后的纤维蛋白原水平

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-09-01 DOI: 10.1016/j.bvth.2024.100017

Margot DeBot , Christopher Erickson , Terry Schaid , Ian LaCroix , Ernest E. Moore , Christopher Silliman , Mitchell J. Cohen , Angelo D’Alessandro , Kirk C. Hansen

{"title":"Trauma-induced dysfibrinogenemia: the von Clauss assay does not accurately measure fibrinogen levels after injury","authors":"Margot DeBot , Christopher Erickson , Terry Schaid , Ian LaCroix , Ernest E. Moore , Christopher Silliman , Mitchell J. Cohen , Angelo D’Alessandro , Kirk C. Hansen","doi":"10.1016/j.bvth.2024.100017","DOIUrl":"10.1016/j.bvth.2024.100017","url":null,"abstract":"<div><h3>Abstract</h3><p>Trauma patients who sustain severe tissue injury and hemorrhage often receive fibrinogen repletion to avert coagulopathy and achieve hemostasis. However, fibrinogen supplementation has not shown a benefit in trauma patients with coagulopathy. The von Clauss functional fibrinogen assay is the primary indication for fibrinogen transfusion. This assay, however, infers fibrinogen levels optically via in vitro clot formation time and does not directly measure the quantity or quality of plasma fibrinogen. We hypothesized that the Clauss fibrinogen activity assay does not accurately reflect true fibrinogen levels in severely injured patients. Here, we demonstrate normal baseline plasma fibrinogen levels as measured by mass spectrometry despite coagulopathic Clauss values in severely injured patients. This discrepancy is most significant in patients with coagulopathy (international normalized ratio of >1.3) or with high shock, and persists even after fibrinogen repletion. These data highlight the need to reevaluate clinical testing of fibrinogen activity and transfusion criteria for the critically injured, and indicate that correcting shock and the oxidative, inflammatory milieu of trauma may be more effective at improving fibrinogen activity. This trial was registered at <span><span>www.ClinicalTrials.gov</span><svg><path></path></svg></span> as #NCT01838863.</p></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"1 3","pages":"Article 100017"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950327224000172/pdfft?md5=5880916926772cd8bc0dccf15d720b5a&pid=1-s2.0-S2950327224000172-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141706753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy EASIX和m-EASIX可预测CAR T细胞疗法后的严重细胞因子释放综合征和总生存率

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-08-21 DOI: 10.1016/j.bvth.2024.100025

Eleni Gavriilaki , Ifigeneia Tzannou , Ioannis Batsis , Ioannis Tsonis , Maria Liga , Konstantinos Gkirkas , Maria Ximeri , Panagiotis Dolgyras , Vasiliki Bampali , Paschalis Evangelidis , Zoi Bousiou , Anna Vardi , Christos Demosthenous , Eulampia Stroggyli , Maria Bouzani , Eleftheria Sagiadinou , Despina Mallouri , Tatiana Tzenou , Damianos Sotiropoulos , Stavros Gigantes , Ioannis Baltadakis

引用次数: 0